SM
PCVX icon

Sabby Management’s Vaxcyte PCVX Stock Holding History

Sabby Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66,483
Closed -$1.69M – 204
2021
Q3 		$1.69M Sell
66,483
-51,511
-44% -$1.25M 0.23% 59
2021
Q2 		$2.66M Sell
117,994
-60,998
-34% -$1.25M 0.37% 37
2021
Q1 		$3.54M Buy
+178,992
New +$4.5M 0.69% 25

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's PCVX Position: Q4 2021 in Review

Sabby Management sold out of Vaxcyte (PCVX) in Q4 2021, closing a stake of 66,483 shares — an estimated $1.69M sold.

Sabby Management first reported a position in PCVX in Q1 2021 and held it in 3 quarters. The position peaked at $3.54M in Q1 2021. 87 funds tracked by Wall St. Rank hold PCVX as of Q4 2021.

  • Sabby Management reported no remaining Vaxcyte position as of Q4 2021 after selling out during the quarter.
  • Sabby Management sold 66,483 Vaxcyte shares in Q4 2021, an estimated $1.69M.
  • Sabby Management first reported a position in Vaxcyte in Q1 2021 and held it in 3 quarters.
  • Sabby Management's Vaxcyte position peaked at $3.54M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.